

Macquarie Conference

May 2015

Andrew Sudholz

Managing Director and CEO

Solid first half result, FY2015 guidance reconfirmed, interim dividend paid

1HFY15 highlights

- Total revenue of \$137.5 million up 13.8% on pro forma 1HFY14
- EBITDA of \$25.5 million up 28.1% on pro forma 1HFY14
- NPAT of \$15.8 million, EPS of 6.0 cents per share
- Interim dividend of 5.5 cents per share (unfranked)
- Net RAD cash inflows of \$45.0 million, exceeding expectations
- Net cash as at 31 December 2014 of \$48.7 million (cash held of \$74.0 million)
- Occupancy of 94.4%, 1.3% ahead of 1HFY14
- 100% re-accreditation of seven facilities reviewed
- 465 additional places awarded in 2014 Aged Care Allocation Round (ACAR), supporting future developments

FY2015 guidance reconfirmed

- Remain on target to deliver EBITDA of \$50.3 million
- Expected FY15 total dividend of at least 10.5 cents per share
- Net cash inflows from RADs expected to exceed \$77.3 million prospectus forecast

RESULTS SUMMARY

Strong 1HFY15 growth versus pro forma 1HFY14; consistent with prospectus forecasts

	1HFY15 Actual (\$ million)	1HFY14 Pro Forma (\$ million)	Change
Total revenue ⁽¹⁾	137.5	120.8	+13.8%
Total costs	112.0	100.9	+11.0%
EBITDA	25.5	19.9	+28.1%
EBIT	20.8	15.4	+35.1%
NPAT	15.8		
EPS	6.0 cps		
Interim dividend ⁽²⁾	5.5 cps		
Net cash position	48.7		

(1) Includes \$0.7 million net gain on Whelan acquisition

(2) Interim dividend is unfranked and was paid on 30 April 2015.


OPERATIONAL AND FINANCIAL METRICS

Key performance indicators tracking in line with expectations

	1HFY15 Actual	1HFY14 Pro Forma	Change
Number of facilities (as at 31 December)	39	35	+11.4%
Operational places (as at 31 December)	3,171	2,857	+11.0%
Average occupancy	94.4%	93.2%	+1.3%
Average ACFI (per resident per day)	\$170.81	\$166.84 ⁽¹⁾	+2.4%
Average annualised EBITDA per occupied place (before head office costs)	\$21,761	\$18,906	+15.1%
Average staff costs to total revenue	65.4%	67.4%	(3.0%)
Average RAD received (cash)	\$309,000	\$267,000	+15.7%
Payment preference of non concessional residents as at 31 December:			
• RAD	79.2%		
• DAP	17.7%		
• Combination of RAD and DAP	3.1%		

(1) 1HFY14 ACFI of \$147.09 adjusted for; 8.75% CAP (Conditional Adjustment Payment), 1.86% of COPE (Commonwealth Own Purpose Expense Indexation) and the Workforce Supplement redirection of 2.4% to show like for like FY15 funding comparative

Strong cash generation to fund further investment in growth and dividends



Japara has three priorities to build strong and sustainable returns to shareholders

1. Maintain a high level of resident care and a safe workplace
2. Maximise the value in our current portfolio – organic growth
3. Maintain our track record of delivering profitable expansion – developments and selective acquisitions

1. MAINTAIN A HIGH LEVEL OF RESIDENT CARE AND A SAFE WORKPLACE

Commitment to quality care; strong compliance record

First half FY2015 progress

Accreditation

- Seven facilities were reassessed during 1HFY15
- Each facility accredited on a rolling 3 year basis with 44/44 outcomes (full compliance)
- Entire portfolio remains fully compliant and accredited
- Consistent positive feedback from government assessment teams on our care model and systems

Health and safety

- Lost Time Injury Frequency Rate consistently below national average

Systems

- Workforce management system vendor selected and capital approved

2HFY15 actions

Accreditation

- Additional six re-accreditations in 2HFY15

Health and safety

- Continuous program of initiatives to maintain high workplace health and safety standards

Systems

- Workforce management system implementation commenced with Kronos
 - Continued focus on operational efficiencies via systems
-

2. MAXIMISE THE VALUE IN OUR CURRENT PORTFOLIO

Good progress in 1HFY15 with further improvements still to be delivered

First half FY2015 progress

ACFI

- Average ACFI for 1HFY15 of \$170.81; average ACFI for pro forma 1HFY14 \$147.09 (\$166.84 for comparison)
- Dedicated team reassessed acuity levels resulting in 2.7% increase in funding reflecting resident care requirements

Occupancy

- Average occupancy for 1HFY15 of 94.4% showed improvement versus 93.2% for pro forma 1HFY14

Staff Costs

- Agency reduced by 12% compared with pro forma 1HFY14
- Overtime loading liability continues to be approximately \$5 million in total; FY15 impact of approximately \$0.25 million; payments commenced

2HFY15 actions

ACFI

- Resident assessment program continues to ensure funding commensurate with acuity and care needs

Occupancy

- Opportunity for improvement; current focus on maintaining all facilities at or above target occupancy

Staff Costs

- Final overtime loading payments
- Enhancements to master roster

2. MAXIMISE THE VALUE IN OUR CURRENT PORTFOLIO

Good progress in 1HFY15 with further business enhancements underway

First half FY2015 progress

Additional Service

- Wellbeing services offer introduced into 10 facilities during 1HFY15; ramp-up to date slower than expected

RADs

- Average RAD value improved to \$309k versus pro forma 1HFY14 of \$267k

Update

Additional Service

- Introduction of further additional services underway
- Will continue to refine and enhance offer in response to resident demand and preferences
- Opportunity significant with additional revenue anticipated at circa \$8m from existing portfolio once fully embedded
- Price points of \$25, \$45 & \$65 per day across a total of circa 500 residents.

RADs

- Completed review of RAD/DAP pricing and incentives to maximise value
- Additional RAD inflow of circa \$150m over three years from previously unbonded (high care) places in existing portfolio to fund future growth
- RAD uplift YTD of \$64m, applied towards Whelan acquisition and accelerated developments program

3. MAINTAIN OUR RECORD OF PROFITABLE EXPANSION

Accelerating internally generated growth opportunities

First half FY2015 progress

Developments

- Three projects already underway
- Remaining projects timeline accelerated

Acquisitions - Whelan

- Completed Whelan Care acquisition on 31 October which added 258 places; performance to date in accordance with acquisition case

Acquisitions – New

- Actively reviewing several new opportunities but vendor expectations have increased; expect regulatory/ funding changes will increase opportunities

Update

Developments

- Brownfield and Greenfield program accelerated
- 725 net new beds programmed to be delivered by 2018
- Phase 1 to deliver approximately 295 net new beds by 2017; all required land held and majority of licences
- Phase 2 to deliver 430 net new beds by 2018; majority of licences already held, further land required

Acquisitions - Whelan

- On track to deliver FY15 EBITDA contribution of \$1.4m post integration costs from Whelan
- Trevu construction on track
- Whelan on track to contribute \$4m+ in EBITDA once fully ramped up

Acquisitions – New

- Disciplined and selective approach
- < 500 places – groups where Japara can enhance operations and returns
- > 500 places – Portfolios where appropriate

Portfolio improvements and developments provide platform for future growth

Current aged care portfolio performing well

- Consistent top quartile financial performance
- Strong focus on delivery of high quality care, and resident and staff safety
- Opportunities to add further value:
 - Continuing program to ensure ACFI entitlements reflect resident acuity/care requirements
 - Management of occupancy levels; maintaining all facilities at or above target occupancy
 - Refining and accelerating additional service offering
 - Cost reduction through further prudent expense management

FY15 guidance reconfirmed

- Remain on target to deliver EBITDA of \$50.3 million
- Expected full year dividend of at least 10.5 cents per share

Growth opportunities remain in place for FY16+

- Greater focus on internally generated brownfield and metropolitan greenfield developments
- Acquisitions continue to be pursued selectively
- Supported by strong cash generation and balance sheet

APPENDIX 1: OCCUPANCY AND OPERATIONAL ANALYSIS

Metrics for full half	1HFY15	1HFY14	Change
Average occupancy rate	94.4%	93.2%	1.3%
Resident mix			
Concessional	33.9%	39.1%	(13.3%)
RAD	52.4%		
DAP	11.7%		
Combination	2.0%		
Average length of stay (months)	29	29	-
Revenue and profitability			
Average ACFI per resident per day (\$)	170.8	166.8 ⁽¹⁾	2.4%
Average EBITDA per resident before head office costs (\$)	21,761	18,906	15.10%
EBITDA margin	18.5%	16.3%	13.5%
Staffing			
Staff costs as a % of total costs	80.3%	80.7%	(0.5%)
Staff costs as a % of total revenue	65.4%	67.4%	(3.0%)
Number of staff as at 31 December (including part time and casuals)	4,379	4,075	7.5%
DAP/RAD			
Proportion of portfolio bonded	43.4%	35.2%	23.3%
Average RAD value received (cash) (\$)	309,000	267,000	15.7%
Net RAD inflow/ (outflow) (\$ million)	45.0	9.2	489.1%

(1) 1HFY14 ACFI of \$147.09 adjusted for; 8.75% CAP (Conditional Adjustment Payment), 1.86% of COPE (Commonwealth Own Purpose Expense indexation) and the Workforce Supplement redirection of 2.4% to show like for like FY15 funding comparative

APPENDIX 2: PORTFOLIO METRICS (AS AT 31 DECEMBER)

	As at 31 Dec 14	As at 31 Dec 13	Change
Number of facilities	39	35	11.4%
Average ACFI (per resident per day)	\$177.2	\$166.3 ⁽¹⁾	6.5%
Average RAD received in December (cash)	\$317,000	\$272,000	16.5%
Places			
Operational places	3,171	2,857	11.0%
Non-operational places	164	139	18.0%
Allocated in ACAR	465	-	100.0%
Total places	3,800	2,996	26.8%
Average facility size (number of places)	84	84	-
Average age of facilities (years)	13	12	8.3%
Geographic spread (facilities)			
Victoria	79.5%	88.5%	-10.2%
NSW	5.1%	5.7%	-0.6%
SA	12.8%	2.9%	9.9%
TAS	2.6%	2.9%	-10.3%

(1) Average portfolio ACFI for December 2014 of \$146.65 adjusted for; 8.75% CAP (Conditional Adjustment Payment), 1.86% of COPE (Commonwealth Own Purpose Expense indexation) and the Workforce Supplement redirection of 2.4% to show like for like FY15 funding comparative

APPENDIX 3: DETAILED PROFIT & LOSS

	1HFY15 Actual (\$ million)	1HFY14 Pro Forma (\$ million)	Change	Change (\$ million)
Revenue				
Government	102.3	91.4	11.9%	10.9
Resident	24.3	21.7	12.0%	2.6
Accommodation	9.0	7.5	20.0%	1.5
Other ⁽¹⁾	1.9	0.2	950.0%	1.7
Total revenue	137.5	120.8	13.8%	16.7
Expenses				
Staff	(89.9)	(81.4)	10.4%	(8.5)
Resident	(9.5)	(7.9)	20.2%	(1.6)
Other	(12.6)	(11.6)	8.6%	(1.0)
Total expenses	(112.0)	(100.9)	11.0%	(11.1)
EBITDA	25.5	19.9	28.1%	5.6
Depreciation and amortisation	(4.7)	(4.5)	4.4%	(0.2)
EBIT	20.8	15.4	35.1%	5.4
Net interest expense	(0.5)			
Income tax expense	(4.5)			
NPAT	15.8			

(1) Includes \$0.7 million net gain on Whelan acquisition

APPENDIX 4: DETAILED CASHFLOW STATEMENT

	1HFY15 Actual \$'000	1HFY14 Pro forma \$'000
CASH FLOWS FROM OPERATING ACTIVITIES:		
Receipts from customers	148,779	136,295
Payments to suppliers and employees	(111,550)	(104,573)
Income tax paid	-	(2,874)
Interest received	1,032	456
Finance costs	(1,666)	(5,298)
Net cash provided by operating activities	36,595	24,006
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of land and buildings	(4,931)	-
Proceeds from sale of land	716	-
Purchase of plant and equipment	(1,553)	(1,249)
Capital works in progress	(8,074)	(16,651)
Purchase of resident places	(493)	-
Purchase of units in related parties	-	-
Acquisition of aged care business	(23,814)	(14,422)
Other acquisition related costs	(6,282)	-
Net cash used in investing activities	(44,431)	(32,322)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Loans repaid by other related parties	-	-
Proceeds from bank borrowings	25,000	8,253
Repayment of bank borrowings	(15,000)	(11,707)
Proceeds from vendor loans	-	1,817
Dividends paid	-	(7,301)
Proceeds from issue of unit capital	-	34,015
Equity raising costs	(1,265)	-
Proceeds from accommodation bonds/RADs and ILU resident loans	74,498	37,047
Repayment of accommodation bonds/RADs and ILU resident loans	(29,531)	(27,824)
Net cash provided by financing activities	53,702	34,300
Net increase (decrease) in cash and cash equivalents held	45,866	25,984
Cash and cash equivalents at beginning of year (30 June)	28,107	20,615
Cash and cash equivalents at end of the half year (31 December)	73,973	46,599

APPENDIX 5: BALANCE SHEET AS AT 31 DECEMBER 2014

	31 December 2014 \$'000	30 June 2014 \$'000
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	73,973	28,107
Trade and other receivables	9,932	7,073
Current tax receivable	-	2,702
Other assets	5,387	3,585
TOTAL CURRENT ASSETS	89,292	41,467
NON-CURRENT ASSETS		
Trade and other receivables	2,214	1,210
Financial assets	1,093	-
Property, plant and equipment	374,188	340,799
Investment property	30,702	23,312
Deferred tax assets	15,173	15,050
Intangible assets	411,793	383,042
TOTAL NON-CURRENT ASSETS	835,163	763,413
TOTAL ASSETS	924,455	804,880
LIABILITIES		
CURRENT LIABILITIES		
Trade and other payables	34,202	20,320
Other liabilities	9,471	9,331
Borrowings	25,255	15,817
Income tax payable	1,494	-
Other financial liabilities	294,303	220,904
Short-term provisions	26,071	22,527
TOTAL CURRENT LIABILITIES	390,796	288,899
NON-CURRENT LIABILITIES		
Long-term provisions	2,322	1,994
TOTAL NON-CURRENT LIABILITIES	2,322	1,994
TOTAL LIABILITIES	393,118	290,893
NET ASSETS	531,337	513,987

DISCLAIMER

- This presentation was prepared by Japara Healthcare Limited (ABN 54 168 631 052), the Company. Information contained in this presentation is current as at 6 May 2015. This presentation is provided for information purposes only and has been prepared without taking account of any particular reader's financial situation, objectives or needs. Nothing contained in this presentation constitutes investment, legal, tax or other advice. Accordingly, readers should, before acting on any information in this presentation, consider its appropriateness, having regard to their objectives, financial situation and needs, and seek the assistance of their financial or other licensed professional adviser before making any investment decision. This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the subscription for, purchase or sale of any security, nor does it form the basis of any contract or commitment.
- Except as required by law, no representation or warranty, express or implied, is made as to the fairness, accuracy or completeness of the information, opinions and conclusions, or as to the reasonableness of any assumption, contained in this presentation. By reading this presentation and to the extent permitted by law, the reader releases the Company and its affiliates, and any of their respective directors, officers, employees, representatives or advisers from any liability (including, without limitation, in respect of direct, indirect or consequential loss or damage or loss or damage arising by negligence) arising in relation to any reader relying on anything contained in or omitted from this presentation.
- The forward looking statements included in this presentation involve subjective judgment and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to, the Company. In particular, they speak only as of the date of these materials, they assume the success of Japara Healthcare Limited's business strategies, and they are subject to significant regulatory, business, competitive and economic uncertainties and risks. Actual future events may vary materially from forward looking statements and the assumptions on which those statements are based. Given these uncertainties, readers are cautioned not to place reliance on such forward looking statements. Past performance is not a reliable indicator of future performance.